About Intra-Cellular Therapies (ITCI)

The current price per share for Intra-Cellular Therapies (ITCI) is $131.87. The stock has seen a price change of -$0.02 recently, indicating a -0.02% change. This reflects the stock's recent market performance and investor sentiment.

For Intra-Cellular Therapies (ITCI), the 52-week high is $131.97, which is 0.08% from the current price. The 52-week low is $45.5, the current price is 189.82% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

Intra-Cellular Therapies (ITCI) has shown an average price growth of -1.65% over the past three years. It has received a score of 86 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Intra-Cellular Therapies as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

As of the latest data, Intra-Cellular Therapies (ITCI) has a year-to-date price change of 57.89%. Over the past month, the stock has experienced a price change of 0.45%. Over the last three months, the change has been 57.51%. Over the past six months, the figure is 82.52%. Looking at a longer horizon, the five-year price change stands at 815.76%.

Intra-Cellular Therapies (ITCI) has a net income of -$74.68M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 91.63% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -14.66% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $680.85M, with a revenue growth rate of 46.62%, providing insight into the company's sales performance and growth. The gross profit is $623.89M. Operating income is noted at -$116.72M. Furthermore, the EBITDA is -$116.21M.

Intra-Cellular Therapies (ITCI) has a market capitalization of $14.05B. The average daily trading volume is 131.9, indicating the stock's liquidity and investor engagement.